GOOD DD READ
Ironwood Pharmaceuticals Whittled Down
Tolerability data for Synergy Pharma’s chronic idiopathic constipation treatment top Ironwood’s Linzess.
Synergy Pharmaceuticals ( SGYP ) reported positive data for plecanatide in a Phase 3 study of 1,346 patients with chronic idiopathic constipation (CIC). Synergy Pharma’s results are favorably to the results from Ironwood’s two CIC trials. Also importantly, tolerability data to favor plecanatide over Linzess
By: Bret Kenell
Fitbit has unbelievable growth and is already profitable, which is a big deal for a newly public company.
The valuation is attractive, too. GoPro (GPRO) and Under Armour (UA) both have slower growth rates, yet have higher valuations that Fitbit. If Fitbit traded with the same valuation as Under Armour, it would be $72.
Fitbit is bringing its fitness wearables to India
Kunal Sehgal & Maria Thomas
The world’s largest wearables company is coming to India.
Founded in 2007, Fitbit commands 85% of the global health wearables market Demand for wearables is surging around the world, with shipments expected to jump 173% this year, according to a report by research firm IDC.San Francisco-headquartered Fitbit will partner with e-commerce firm Amazon to offer four types of wearable bands to help Indian consumers track their fitness
do the DD
CyberArk Files For Secondary Offering After Strong Q1
BY GILLIAN RICH, INVESTOR'S BUSINESS DAILY
6-8-15 08:54 AM ET
CyberArk Software (NASDAQ:CYBR) said Friday it filed for a follow-on stock offering.
The cybersecurity company filed a registration statement with the Securities and Exchange Commission for the secondary offering. The majority of the shares will be sold by current shareholders with $50 million in shares to be sold by CyberArk. The total number of shares to be sold hasn't been decided yet.
Can Get FDA approved Next week :
What Should the FDA Do With the PCSK9 Inhibitor Evolocumab?
( AMGN )
We predict our FDA won't be able to help themselves. In all likelihood, they will allow the star compound of the American College of Cardiology (ACC) 2015 Scientific Sessions, evolocumab (Repatha, Amgen), to come to market without waiting for "hard outcomes." I predict they will do it for a variety ofreasons,chief of which is the irrefutable fact that it lowers LDL levels to nadirs that only genetically blessed, anorexic, exercise-addicted vegetarians can achieve
Bought BLUE at $80 Now $198- CLLS is Next. ..Doubled What I bought BLUE at and bought CLLS.
Sentiment: Strong Buy